Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Hunter, D. J., Khoury, M. J. & Drazen, J. M. Letting the genome out of the bottle — will we get our wish? N. Engl. J. Med. 358, 105–107 (2008).
2. Committee on Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment. Cancer Biomarkers: the Promises and Challenges of Improving Detection and Treatment (eds Nass, S. J. & Moses, H. L.) (National Academies Press, Washington DC, 2007).
3. Ratain, M. J. & Glassman, R. H. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin. Cancer Res. 13, 6545–6548 (2007).
4. Carroll, K. J. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology. Pharm. Stat. 6, 253–260 (2007).
5. Shah, N. P. et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 117, 2562–2569 (2007).
Cited by
802 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献